Health

Dr. Reddy’s introduces generic version of Ciprodex in US Market

Dr. Reddy’s introduces generic version of Ciprodex in US Market

Health

Hyderabad-based Dr. Reddy’s Laboratories Limited has reportedly launched a generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension in the U. S market, after getting approval from the US FDA (Food and Drug Administration).

Ciprodex is generally recommended for the treatment of infections developed by susceptible isolates of established microorganisms under the specific conditions of AOM (Acute Otitis Media) in pediatric and AOE( Acute Otitis Externa) in adult, pediatric, and elderly patients.

Marc Kikuchi, who is the CEO of North America Generics business at Dr. Reddy’s Laboratories seemed to be rather satisfied with the first-to-market product launch and has appreciated the firm

Genentech announces updated Phase III clinical data of Etrolizumab

Genentech announces updated Phase III clinical data of Etrolizumab

Health

Genentech, a biotechnology corporation that operates as an independent unit within Roche Group, has reportedly announced the top-line results from its Phase III clinical trial of etrolizumab in patients with moderately to severely active ulcerative colitis.

Sources cite that studies assessing etrolizumab as an induction therapy demonstrated mixed results. HIBISCUS I induction clinical study in people without prior anti-TNF (Anti-tumor Necrosis Factor) treatment apparently met the primary endpoint.

On the other hand, the HIBISCUS II induction clinical study, which comprised patients without previous anti-TNF treatment, didn’t achieve its primary endpoint.

Studies assessing etrolizumab as a maintenance therapy

WITHmyDOC launches RPM@Home™ kit to aid Healthcare Professionals

WITHmyDOC launches [email protected]™ kit to aid Healthcare Professionals

Health
"

Florida-based healthcare technology company WITHmyDOC has reportedly introduced [email protected]™, a remote patient monitoring (RPM) kit. It is being speculated that the kit may revolutionize the healthcare sector.

Sources cite that [email protected]™ transmits real-time biometric data of patients to healthcare providers using a web-based intelligence platform. [email protected] provides real-time data and facilitates proactive intervention by assisting chronic care management and telehealth visits.

With the help of WITHmyDOC’s RPM platform, healthcare providers will be able to review the patient’s biometric data as regularly as required during office visits. Hence it will make it easier to spot, diagno